A monthly overview of things you need to know as an architect or aspiring architect. Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with ...

Spire Global has won contracts to provide the National Oceanic and Atmospheric Administration's Commercial Weather Data Program with global navigation satellite system (GNSS) radio occultation and ...

Nicole Charky-Chami is a senior editor based in Los Angeles, writing and producing breaking news. She teaches journalism courses for UCLA Extension and previously taught at Loyola Marymount University ...

As college football fans have learned over the past few years, the best thing to expect when it comes to the NCAA transfer portal is the unexpected. Just when we thought that we knew all of the teams ...

WASHINGTON, Dec 30 (Reuters) - President Donald Trump's administration has lifted sanctions on three executives tied to the spy software consortium Intellexa, according to a notice published to the ...

After entering the year ranked No. 2 in the AP Top 25 preseason poll, Penn State endured a turbulent 2025 season that included the firing of long-time head coach James Franklin, a disappointing 3–6 ...

All products featured here are independently selected by our editors and writers. If you buy something through links on our site, Gizmodo may earn an affiliate commission. Reading time 3 minutes ...

Crypto exchange Binance is expanding the role of USD1 (USD1), the stablecoin of Trump-linked crypto project WLFI $0.1202, overhauling part of its stablecoin infrastructure with the token. Starting ...

A new bar and event venue is headed to the former Castro/Duboce Triangle dive bar Lucky 13 at 2140 Market Street. Hoodline was alerted to the change by a liquor license application notice on the ...

Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...

Structure Therapeutics is developing a daily GLP-1 receptor pill called aleniglipron. Structure Therapeutics' stock soared toward an 18-month high in early Monday trading, after mid-stage data for its ...